EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cancer mRNA vaccines: clinical application progress and challenges

Hang Li, Lang Min, Haotian Du, Xiawei Wei, Aiping Tong

Cancer Letters · 2025-08 · 625 · 217752

DOI: 10.1016/j.canlet.2025.217752 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025-08. Verfasst von Hang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Inn…. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, mRNA Vaccines, RNA, Messenger. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 145 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) vaccines have emerged as one of the most promising and rapidly evolving immunotherapeutic approaches due to their ease of production, demonstrated clinical efficacy, and high safety. The coronavirus disease 2019(COVID-19) pandemic has showcased the remarkable therapeutic potential of mRNA vaccines, prompting researchers to explore their use for cancer treatment. Preclinical studies and human clinical trials have indicated their substantial clinical applicability. However, current research faces several challenges, including the complexity of tumor antigen selection, vaccine stability, and the development of resistance. This review summarizes the optimization strategies for cancer mRNA vaccines in preclinical settings, the progress of clinical trials, and the challenges encountered while analyzing various delivery vehicle types, infusion methods, and application cases across different cancer types, highlighting key factors in vaccine design. The findings demonstrate that mRNA vaccines elicit specific immune responses and exhibit favorable safety and tolerability in clinical trials. Moreover, developing personalized neoantigen vaccines offers a novel direction for cancer immunotherapy. The unique contribution of this review lies in its comprehensive overview of the latest advancements in therapeutic mRNA vaccines for cancer treatment while identifying critical areas for future research to propel the field forward.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsmRNA VaccinesRNA, MessengerHumansCOVID-19ImmunotherapySARS-CoV-2Antigens, NeoplasmAnimalsClinical Trials as TopicVaccines, Synthetic

Stichwörter der Autor:innen

Cancer immunotherapyCombination therapyPersonalized vaccinesRNA vaccines

Substanzen

Cancer VaccinesmRNA VaccinesRNA, MessengerAntigens, NeoplasmVaccines, Synthetic

Autor:innen und Institutionen

  • State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University,…
  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Laboratory of Aging Research and Cancer Drug Target, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
  • State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Electronic address: aipingtong@scu.edu.cn.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Li, H., Min, L., Du, H., Wei, X., & Tong, A. (2025). Cancer mRNA vaccines: clinical application progress and challenges. Cancer Letters, 625, 217752. https://doi.org/10.1016/j.canlet.2025.217752

Vancouver

Li H, Min L, Du H, Wei X, Tong A. Cancer mRNA vaccines: clinical application progress and challenges. Cancer Letters. 2025;625:217752. doi:10.1016/j.canlet.2025.217752

BibTeX
@article{Li2025,
  author = {Li, Hang and Min, Lang and Du, Haotian and Wei, Xiawei and Tong, Aiping},
  title = {Cancer mRNA vaccines: clinical application progress and challenges},
  journal = {Cancer Letters},
  year = {2025},
  volume = {625},
  pages = {217752},
  doi = {10.1016/j.canlet.2025.217752}
}
Kostenlos starten →